Dopamine D2-receptor density in striatum of monkey was measured with 3-(2' -[18F]fluoroethyl) spiperone (FESP) and dynamic positron emission tomog raphy (PET), using a double-injection technique. A first bolus of high specific activity (SA) FESP (5 mCi; = 1 Ci/fLmoi) was injected i. v.; 90 min later, a second bolus of lower SA FESP (5 mCi; = 0.04 CiJfLmol) was injected. A dynamic PET study was performed to measure the kinet ics of FESP in striatum over 180 min, and the metabolite corrected concentration of FESP in plasma as a function of time was obtained from arterial blood samples. A non linear compartmental model that took into account the saturability of the receptor binding was used to describe Abbreviations used: BBB, blood-brain barrier; FESP, 3-(2' -eBF]fluoroethyl)spiperone; FWHM, full width at half maximum; NMSP, 3-N-[1IC]methylspiperone; PET, positron emission tomography; PS, permeability-surface; ROI, region of interest; RSS, residual sum of squares; SA, specific activity. Welch MJ, Katzenelienbogen JA, Mathias CJ, Brodeck JW, Carlson KE, Chi DY, Dence CS, Kilbourn MR, Perlmutter JS, Raichle ME, Ter-Pogossian MM (1988) (3-[lSF]fluoro propyl)spiperone: the preferred lsF labeled spiperone analog for positron emission tomographic studies of the dopamine receptor. Nucl Med Bioi 15:83-97
A number of dopamine D2-receptor binding ligands have been successfully labeled with posi tron emitters (Fowler et aI., 1982; Shiue et aI., 1985 Shiue et aI., ,1986 Burns et aI., 1984; Maziere et aI., 1984; Satyamurthy et aI., 1986; Welch et aI., 1988; Ehrin et aI., 1985) and have been used for assessing the density and binding characteristics of dopamine D2receptors in humans/primates in vivo with positron the kinetics of FESP in striatum. Model parameters were estimated by regression with a constraint based on infor mation about the equilibrium dissociation constant of the ligand-receptor binding. Dopamine D2-receptor density in striatum was estimated to be 25.9 ± 12.7 pmoUg in seven Macaca nemestrina monkeys. The method does not require the use of cerebellum as a reference tissue region and an estimate of dopamine D2-receptor density can be obtained from a single study. Key Words: Dopam ine D2-receptors-Dynamic positron emission tomogra phy (PET)-3-(2' -[ 18F]fluoroethyl)spiperone (FESP) Double-injection tracer kinetics-Nonlinear model. emission tomography (PET) (Wagner et aI., 1983; Wong et aI., 1986a,b; Farde et aI., 1986; Baron et aI., 1986) . In general, the study method used in these measurements can be categorized into dy namic and equilibrium approaches depending on whether or not the time-varying radioactivities of the tracer in tissue and plasma are used (Huang et aI., 1986a) . Although all of the existing study meth ods are based on similar tracer kinetic models (Huang et aI., 1986a) , they have different study pro cedures and different assumptions. Mintun et ai. (1984) and Perlmutter et ai. (1986) used eSF]spiperone and a dynamic approach to ex amine the dopamine D2-receptors in primates. They estimated the ratio of Bmax / KD ' called the "binding potential," to be 19.4 pmol/g/nM in the striatum of baboons, where Bmax was the receptor density and KD was the equilibrium dissociation of the binding between the ligand and the receptor. Wong et al. (1984) used 3-N-[1lC]methylspiperone (NMSP) and showed that the slope of the caudate-to-cerebellum radioactivities ratio vs. time decreased as a function of age in normal human subjects. They suggested that such a slope would be proportional to dopam ine D2-receptors in the caudate. Wong et al. (1986a) reported a dynamic technique (with NMSP) that re quired two studies on a subject-one before and one after an oral dose of haloperidol. The technique estimated a value of 9.2 pmol/g for the dopamine D2-receptor density in caudate nucleus of humans. They have also applied the technique to schizo phrenic patients and found increased caudate dopamine D2-receptor density in these patients (Wong et aI., 1986b) . Farde et al. (1986) found using [llC] raclopride that the equilibrium tracer concen tration in caudate as a function of the mass dose followed the hyperbolic relationship [bound = Bmax x free/(KD + free)] used in the in vitro receptor assay. With such a relationship and the PET measured equilibrium concentrations of [llC]raclo pride in putamen and cerebellum, they estimated the dopamine D2-receptor density in human puta men to be 14.4 pmollg. Most of these methods use the kinetics or concentration in the cerebellum as a reference for the nonspecifically bound fraction of the tracer in the striatum, although there are differ ences between the striatal and cerebellar tissue that can potentially cause significant errors in the esti mation. Also, the existing techniques that provide direct estimates of the receptor density all require multiple (at least two) separate studies. Potential repositioning inaccuracy and physiological varia tions of the subject between the separate studies could also introduce large measurement errors.
In this paper, we report a method of using double injections of 3-(2,-[18F]fluoroethyl)spiperone (FESP) (Barrio et aI., 1986; Satyamurthy et aI., 1986) for measuring the density of dopamine D2-receptors in primates with PET. The method does not require the use of cerebellum as a reference tissue region and an estimate of Bmax can be obtained from a single study.
METHODS

Synthesis of FESP
The synthesis of FESP was according to the method developed by Satyamurthy et al. (1986) . The specific ac tivity (SA) of the tracer ranged from 1 to 10 Ci/fl-mol. Lower SA FESP was obtained by adding unlabeled FESP to the high SA tracer.
PET study
Seven monkeys (Macaca nemestrina) (5-10 kg) were studied. Two hours before the study, the animals were anesthetized with ketamine (= 15 mg/kg) and intubated.
The animals were later maintained under barbiturate an esthesia (= 12 mg/kg/h). An arterial catheter was placed in the femoral artery for blood sampling. The animal was placed supine on a NeuroECAT PET scanner. The ani mal's head was properly positioned and constrained by tape in such a way that both the striatum and the cere bellum regions of the brain were in the scanned plane. Oxygen-IS water rectilinear scans (Hoffman et aI., 1983) were used to assist the positioning.
The high-resolution scanning mode with the "septa in," "shields-in" option of the NeuroECAT scanner was used for the scanning (Hoffman et aI., 1983) . A transmis sion scan was first taken to measure attenuation in the scanned cross section for later use in attenuation correc tion. A bolus of high SA FESP (5 mCi) was injected i.v. and, simultaneously, a sequence of PET scans (ten 1.5min, nine 5-min, and three 10-min scans) was started. A series of arterial blood samples (0.5 ml each) was taken at a rate of five per minute during the first 2 min and at a gradually slower rate thereafter until 90 min after the in jection, with a total of about 20 samples. At 5, 10, 15, 35, 60, and 90 min, a separate set of arterial blood samples (4 ml) was taken for chemical assay of labeled metabolites (Barrio et aI., 1989) . After the first scanning sequence was over (at about 90 min), a second bolus of FESP of lower SA (= 0.04 Cilfl-mol; 5 mCi) was injected and an identical sequence of PET scans was initiated. A second series of arterial blood samples (including those for chemical as says of labeled metabolites) was taken following the same time sequence as the first series. The blood pressure and blood gases (p02 and pC02) were monitored throughout the study and remained normal.
In one additional study, a 50 fl-g FESP dose (i.e., with out F-18 radioactivity) was used in a second injection (i.e., at 90 min) to examine the magnitude of radioactive plasma FESP at time >90 min that is due to the first injection. This mass dose was similar to the total mass dose of the labeled FESP in the second injection of the above protocol. The same blood sampling schedule as for the other studies was used.
Arterial plasma FESP concentrations were assayed chemically according to the procedure previously de scribed (Barrio et aI., 1989) . These chemically determined data were used to determine the corrected FESP activity curve in plasma as described previously (Bahn et aI., 1989) .
The PET images were reconstructed with the medium resolution filter of the NeuroECAT scanner with a result ant spatial imaging resolution of 0.95 cm full width at half-maximum (FWHM). Regions of interest (ROIs) were drawn on the PET images to define the regions of striatum and cerebellum (Bahn et aI., 1989) . These ROIs were ap plied to all images of a study and time-activity curves of F-18 in the defined tissue regions were then obtained.
Model equations for FESP kinetics
The model configuration used for describing the kinet ics in striatum is shown in Fig. 1 of the accompanying paper (Bahn et aI., 1989) , which has also listed the model assumptions, and the symbols used. However to account for the two separate injections, the set of differential equations for describing the FESP radioactivity in stria tum needs to be expanded as follows:
Cb l = k J2Bm a xCf l -kdCb 1k J2Cn (Cbl/SAI + CbzfSA2 )
where the subscripts 1 and 2 for Cp (!-lCi/mi), Cf (!-lCi/g), Cb (!-lCi/g), and SA (CiI!-lmoi) are used to denote the com ponents due to the first and the second injections, respec tively; K/ is the same as KI except it is for the FESP due to the second injection (of lower SA). Two different KI values were used to account for potential SA dependency of KI• The PET measured tissue activity at time t is equal to the sum of Cbl, Cn, Cb2 and Cn plus the contribution of the radioactivity in the vasculature. The radioactivity in the vasculature was approximated as 0.05 mUg times the total F-18 radioactivity concentration in blood. The above nonlinear differential equation was solved using numerical integration (fourth order Runge-Kutta) with a step size of 5 s. The particular step size was used because no improvement on the accuracy of the solution was ob served with smaller step sizes (e.g., 1 and 2 s).
Data analysis
Each measured plasma FESP curve was first separated into two parts, Cpl and Cp2, corresponding to the two injections. From time 0 to 90 min (before the second in jection), Cp2 was zero. For time larger than 90 min (i.e., after the second injection), the component due to the first injection was linearly extrapolated according to the fol lowing relationship:
The component due to the second injection was obtained from the plasma FESP curve by subtracting the compo nent due to the first injection.
The two plasma FESP components were then used as the input functions Cpl(t) and Cp2(t) in Eq. (1) and the PET measured striatal time-activity curves were fitted with the model equation [Eq.
(1)] to estimate the values of the model parameters. A least-squares criterion was used in the curve fitting (regression) with weightings of each data point inversely proportional to its noise variance as described in the accompanying paper (Bahn et aI., 1989) . The integration of the radioactivity over the scan time (Huang et aI., 1986b) in the tomographically determined tissue time-activity curves was also accounted for. The least-squares regression was performed with the BLD software package (Carson et aI., 1981) .
To improve the convergence and to reduce the stan dard errors (SEM) and the correlations of the estimated parameters (Bahn, 1988) , a constraint on the estimated parameters of striatum with kd/kJ2 = 1 pmol/g was uti lized in the regression. The constraint was according to the following assumptions based on literature results: (1) the affinity of FESP to dopamine D2-receptors (IC50) is similar to that of labeled spiperone (Barrio et aI., 1989) ;
(2) in vitro KD of spiperone binding to dopamine D2receptors is about 0.1 nM (Seeman and Grigoriadis, 1987) ; (3) the dissociation rate of in vivo spiperone bind ing is about five times slower than that of in vitro binding (Chugani et aI., 1985) (i.e., in vivo kd/ka = 0.2 mUg x in vitro kd/ka); (4) an f2 value of 0.02 (Mintun et aI., 1984; Perlmutter et aI., 1986) . Therefore, (in vivo kd/kJ/f2 = (0.2 x in vitro kd/ka)f2 = 0.2 x 0.110.02 = 1 pmol/g.
The time-activity curve in cerebellum was fitted with a linear two-compartment model that has the same config uration as the one shown in Fig. 1 of the accompanying paper (Bahn et aI., 1989) , except that there is no saturable receptor sites [i.e., Eq. (1) with all the nonlinear terms ignored, kd replaced by k4, and kJ 2Bm a x replaced by k3]' This linear model is identical to the model used for [18F]2-fluorodeoxY-D-glucose (Sokoloff et aI., 1977; Bahn et aI., 1989; Huang et aI., 1980) . In the regression, the value of KI for the second injection was also allowed to vary from that of the first injection. No additional con straints were utilized.
RESULTS
The specific activities of FESP used in the seven studies are shown in Table 1 . Five millicuries of SA = 0.04 Ci/flmol corresponded to a mass dose of about 50 flg, or = 7 flg/kg for a 7 kg monkey. No observable pharmacological effects of the injected FESP were present in any of the studied animals. The values of SA corresponded to the time of the first injection.
The time-activity curves of FESP in arterial plasma in a typical double-injection study is shown in Fig. 1 . The peak near 90 min is due to the second FESP injection. Both the total F-18 activity and the metabolite corrected curves are shown. The time- .� activity curves in striatal and cerebellar tissue re gions are shown, respectively, in Figs. 2 and 3 . The plasma FESP curve for the experiment with zero radioactivity in the second injection (i. e. , only a mass dose of 50 J-lg of FESP) is shown in Fig. 4 . In this case, the labeled FESP was all due to the first injection and the extrapolation to the period be tween 90 and 180 min according to Eq.
(2) was also shown in the figure as a comparison to the mea sured values. The least-squares fitting of the striatal time activity curve by the model equation is shown in Fig. 2 . Free and specifically bound FESP as esti mated by the model equation are also shown. The model parameter values estimated from regression for all seven studies are shown in Table 1 . The pa rameter estimates were not found to be sensitive to the initial values used in the regression. The percent occupancies of the specific receptors by the in jected FESP dose averaged 69 ± 17% at 180 min and are also shown in the table. Figure 3 shows a typical fitting of the time activity curve in cerebellum by a linear two compartment model. The relatively poorer fitting as compared to that in striatum (Fig. 2) is believed to be due to the inaccuracy in the correction of vascu lar radioactivity, which usually can be a large compo-nent in cerebellar regions. The estimated model pa rameters for all studies are shown in Table 2 .
DISCUSSION
The first injection of FESP (high SA) used in the double-injection procedure described in this work was not different from that used in other dynamic methods. However, the second injection of FESP of lower SA contained a mass dose sufficient for direct estimation of Bmax separately from that of f2ka ' The significance of the second injection can be explained with the following considerations: If only the tracer FESP of very high SA was used, the non linear terms in the model equation [Eq. (1)] became negligibly small and the parameter Bmax always ap peared along with f2ka in the equation. In other words, the value of Bmax could not be estimated without other independent measurements or as sumptions. This is quite equivalent to the in vitro receptor assays in which multiple concentrations of the binding ligand are needed to provide informa tion about the receptor number (Bmax). The use of a mass dose to occupy a significant fraction of the specific binding receptors is in fact common to all existing in vivo PET techniques that can directly provide Bmax (Wong et aI. , 1986a; Farde et aI. , 1986). Although other injection protocols (e.g., a single injection of medium SA FESP) can also be used to provide Bmax estimates, the present double injection protocol gives more stable estimates of the parameters (Bahn, 1988) . A constraint on the parameters was used in the present study to improve the convergence of the curve fitting. The particular constraint was chosen because independent information about the value of kd1f2ka was available from the literature and because a rather stable value for the ratio was observed in the fitting results even when no constraint was used (Bahn, 1988) . With the constraint, the standard er rors of the estimates were reduced generally by a factor of 2 to 3, and the maximal correlation coef ficient among the parameter estimates were all less than 0.92. The effect of the constraint on the esti mated parameter value was found to be small (e. g. , a 10% error for the constrained value corresponded to a less than 3% change in the Bmax estimate). More importantly, the constraint did not affect the good ness of fit in five of the seven experiments, as judged by the F test (Bahn et aI., 1989) on the change of the residual sum of squares (RSS). In the two other studies, the RSS with the constraint was increased by about 20% (causing the F value to be above the p = 0. 05 threshold), but the fit was still J Cereb Blood Flow Metab, Vol. 9, No.6, 1989 satisfactory based on visual examination of the ran domness of the residual. In other words, the use of the particular constraint did not affect the model's ability to fit the measured kinetics.
The separation of the actual plasma FESP curve from 90 to 180 min into two components due to the two injections was based on Eq. (2), which was shown in Fig. 4 to give a good first-order approxi mation to what was measured in the experiment with zero radioactivity SA in the second injection. Effects of inaccuracy in this separation had also been examined and found to be small. For example, in the extreme case of assuming Cp) = 0 after t > 90 min, the estimate of Bmax was affected in average by less than 6% and less than 5% for other parameters (Bahn, 1988) , The reason for this insensitivity to the separation method is believed to be primarily due to the relative small amount of FESP activity in plasma after 90 min that is due to the first injection.
In the regression, the value of K ) was allowed to be different between the first and second injections.
The introduction of an extra K ) (K ) f) was not needed for some studies, but it was used to keep the data processing consistent among all studies. The results show that on average the K ) value is larger for the second injection (lower SA). The value of K )
is primarily related to the permeability-surface (PS) (1) with the nonlinear terms ignored] is also shown.
product of the capillary and the fraction ifl) of FESP in plasma free to cross capillaries (Mintun et aI., 1984) . Thus, the increase in KI of the second injection could be explained by an increase in the free FESP fraction II in plasma relative to the frac tion bound to plasma proteins as a result of a larger mass dose of FESP. This is consistent with the ob servation that the KI increase in striatum correlates well with that in the cerebellum (correlation coeffi cient r = 0.99), indicating that the KI increase is most likely due to changes in the plasma FESP that are common to both tissue regions.
Although peripheral FESP metabolites could po tentially cross the blood-brain barrier (BBB) and enter tissue regions, this was found to have minimal significance within the time of the experiment (Bahn et aI., 1989) . For striatum, this was especially true, because, compared to the relatively high ra dioactivity level of FESP in striatum (>90% up to 4 h in rats), the metabolite fraction was negligible and thus should not have much effect on the results ob tained in the present study (Barrio et aI., 1989) .
Using the double-injection procedure, dopamine D2-receptor densities in striatum (Bmax) of Macaca nemestrina monkeys were estimated to be 25.9 ± 12.7 pmol/g. These results are comparable to those obtained in vitro with the same monkey species (Barrio et aI., 1987) . The Bmax value is also consis-tent with the value of 26 pmol/g obtained for Macaca Iascicularis monkeys (Seeman, personal communication) . Potential sources of variability of the Bmax value among the different studies include, in addition to statistical factors, the partial volume effects due to the small size of the monkey striatum and the limited spatial resolution of the Neuro EeAT tomograph (Hoffman et aI. , 1979) , the heter ogeneity of receptors (dopamine D2 and serotonin S2) in striatum (Seeman and Grigoriadis, 1987) , ef fects of anesthesia, and experimental factors such as positioning, ROI definition, and variability of plasma metabolite fractions and specific activities of the radiotracers. FESP kinetics in cerebellum were found to be describable by a linear two-compartment model. This is consistent with similar findings in our labo ratory (Bahn, 1988) and elsewhere (Logan et aI., 1987) . In contrast to other existing methods for de termining dopamine D2-receptor densities, the present method does not require the use of cerebel lum as a reference tissue to account for nonspecific binding. As shown in this and other studies (Bahn et aI., 1989; Logan et aI., 1987) , the cerebellar kinetics of radiolabeled butyrophenone neuroleptics cannot usually be described by a single uniform compart ment, in contrast to the case in striatum where the nonspecifically bound and free ligands are approx- Time (minutes) imated as a single pool. In addition, the transport rate constants of the ligand may be different in stri atum and cerebellum, especially considering that cerebellum is not a uniform tissue (gray and white matter) and presents apparent saturable nonspecific binding kinetics for spiperone (Seeman and Grigo riadis, 1987; Hartley and Seeman, 1978) . However, whether the cerebellum can be used as a reference depends critically on the specific method used as well as on the characteristics of the ligand, and needs to be investigated and determined for each case.
As estimated from the tissue kinetics, due to the mass dose (= 7 fLg/kg) of FESP in the second injec tion, about 70% (Table 1) receptors in striatum were occupied by the injected ligand at 180 min. Although no pharmacological ef fects were observed in the studied animals, the dose is prohibitively large for use in humans. However, the feasibility of using lower mass doses is now be ing investigated in our laboratories. There are many tradeoffs among the mass dose, the estimation reli ability, the study duration, the binding affinity of the labeled ligand, and the sensitivity to the as sumptions used. Preliminary results indicate that the study procedure can be optimized to allow its use in humans (Bahn, 1988) .
CONCLUSION
A double-injection technique using FESP was ap plied with PET for measuring cerebral dopamine D2-receptor densities in monkeys. The method pro vided results comparable to in vitro assay values, but no other in vivo results on dopamine D2receptor density in monkeys are available for com parison. The procedure does not require the use of cerebellum as a reference region. Moreover tomo graphic studies can be completed in a single study, avoiding the need of mUltiple studies that are sus ceptible to subject repositioning errors and other variations. The technique also has high potential for use with other tracers, for the assay of other neu-roreceptor systems, and for measurements ill hu mans.
